Talk:Sarilumab
Jump to navigation
Jump to search
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: |
||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sarilumab.
|
Add mechanism
Could add a brief Mechanism of action section to explain why thought useful for RA and ankylosing spondylitis and any other potential indications ? - Rod57 (talk) 12:21, 24 November 2016 (UTC)
- Could (? should) be added to Anti-IL-6, as this is a class effect, and not limited to one single moiety. WhitePJ 20170421 12:50 —Preceding undated comment added 11:50, 21 April 2017 (UTC)
Other phase 3 trials
The TARGET and MOBILITY trials were also positive - FDA Gives Nod to Sarilumab for Rheumatoid Arthritis 2017 - Rod57 (talk) 17:53, 12 June 2017 (UTC)
EMA (EU) approval
[1] says "The EMA has cleared Kevzara for use in combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to - or who are intolerant to - one or more disease modifying anti-rheumatic drugs (DMARDs)." - but need a better source. - Rod57 (talk) 12:21, 5 July 2017 (UTC)